# A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis

> **NCT00565721** · PHASE2 · COMPLETED · sponsor: **GE Healthcare** · enrollment: 33 (actual)

## Conditions studied

- High-grade Glioma
- Lung Cancer
- Head & Neck Cancer
- Sarcoma
- Melanoma

## Interventions

- **DRUG:** Fluciclatide Injection - (AH111585 (F18))

## Key facts

- **NCT ID:** NCT00565721
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2011-10
- **Final completion:** 2012-09
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00565721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00565721, "A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00565721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*